LLY

$906.70-10.80 (-1.18%)

Market ClosedAs of Mar 20, 8:01 PM UTC

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$906.70
Potential Downside
28.1%
Whystock Fair Value$651.53
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDrug Manufacturers-General

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, in...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$811.51B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
39.52
Beta
Defensive asset. Lower volatility than the S&P 500.
0.43
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
52.01%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.19

Recent News

Simply Wall St.
Mar 21, 2026

Eli Lilly Taps Fauna Bio AI To Expand Long Term Obesity Strategy

Fauna Bio and Eli Lilly (NYSE:LLY) identified a new obesity drug target using AI insights from hibernating mammals. The target designation advances their existing discovery partnership focused on metabolic disease. This development adds a non GLP 1 related angle to Eli Lilly's obesity research efforts. Eli Lilly, known for its diabetes and obesity treatments, is already a central player in the fast growing weight management drug space. The new AI derived target with Fauna Bio gives the...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Investing.com
Mar 21, 2026

Beijing courts Eli Lilly as weight-loss drug race drives $3bn China commitment

Investing.com -- Eli Lilly and Company (NYSE:LLY) is deepening its footprint in the world’s second-largest economy, with Chinese Commerce Minister Wang Wentao expressing hope that the pharmaceutical giant will "deepen its commitment" and pursue more aggressive growth targets.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Financial Times
Mar 20, 2026

Big drugmakers saved at least $5bn on US taxes shifting income overseas

Ten of the biggest US pharmaceutical and biotech companies cut at least $5bn from their federal tax bills last year by booking income in low...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Yahoo Finance Video
Mar 20, 2026

Market Madness: Palantir, Walmart, & other hot stock picks

In the second installment of Yahoo Finance's "Market Madness" bracket tournament, Zack's Investment Management chief market strategist Brian Mulberry joins Yahoo Finance Head of News Myles Udland to make the case for this round of corporate match-ups, which includes Robinhood (HOOD) vs. UnitedHealth (UNH) Palantir (PLTR) vs. Procter & Gamble (PG), General Motors (GM) vs. Eli Lilly (LLY), Walmart (WMT) vs. Uber (UBER), and more.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Insider Monkey
Mar 20, 2026

Eli Lilly and Company (LLY) Announces Positive Topline Results From the Phase 3 ADorable-1 Trial

Eli Lilly and Company (NYSE:LLY) is one of the best long term stocks to invest in according to billionaires. Eli Lilly and Company (NYSE:LLY) announced on March 16 positive topline results from the Phase 3 ADorable-1 trial that was evaluating the safety and efficacy of EBGLYSS in pediatric patients with moderate-to-severe atopic dermatitis. Management stated that […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.